Risk factor
Very vulnerable to price shocks
Profitability factor
Overvalued vs peers
About
Sansure Biotech Inc., founded in Changsha, China, in 2008, is dedicated to the global development and commercialization of advanced diagnostic and research products. The company offers a diverse range of solutions, including upstream nucleic acid extraction kits, real-time PCR systems for both clinical and investigative purposes, and fluorescence detection platforms. Their extensive product portfolio encompasses diagnostic assays for critical conditions like the novel coronavirus, viral hepatitis, and AIDS. Furthermore, they provide blood screening and general extraction kits, tests for cancer-related biomarkers, and solutions for respiratory, sexually transmitted, digestive tract, prenatal, postnatal, and genetic diseases. Sansure Biotech also supplies essential laboratory instrumentation and various consumables, primarily serving hospitals and scientific laboratories worldwide.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBITDA,